Time-kill assay showing the effect of ivermectin against <i>M</i>. <i>ulcerans</i> over 8-weeks.

<p><i>M</i>. <i>ulcerans</i> was grown in 25cm² culture flasks in the presence of 0, 8 and 20μg/ml ivermectin. Ethanol (solvent for ivermectin) at the concentration in the IVM-20 dose was used in the no-drug control. Weekly, ten-fold dilutions of each culture were plated onto 7H10 agar, using a 3-μl spot-dilution method, with five replicates per dilution. The plates were examined for growth after incubation for 8-weeks at 30°C, and colony forming units per ml calculated. The mean and range for duplicate biological experiments are shown.</p

Minimal inhibitory concentration (MIC) of avermectins compared with rifampicin.

<p>Minimal inhibitory concentration (MIC) of avermectins compared with rifampicin.</p

Clinical presentation of scabies and complications before and after start of the programme.

<p>Clinical presentation of scabies and complications before and after start of the programme.</p

Indication for treatment in the study population before and after start of the SIP by gender and country of origin (total n = 2866).

<p>Indication for treatment in the study population before and after start of the SIP by gender and country of origin (total n = 2866).</p

Flow chart of study participants January 2014 –March 2016, *IVM/PERM = ivermectin/permethrin.

<p>Flow chart of study participants January 2014 –March 2016, *IVM/PERM = ivermectin/permethrin.</p

Density map of the distribution of scabies signs and symptoms at different body parts.

<p>*locations of scabies signs were missing in medical record for 386 patients.</p

MLVA and spa typing of<i>S. aureus</i> isolates from chronic wounds of EB patients.

a<p>VNTR, Variable Number of Tandem Repeats.</p>b<p>MC, molecular complex.</p><p>Per patient, the isolates with closely related <i>spa</i>-types have been marked by ^I or ^II.</p

Spearman's rank correlations, 95% confidence intervals and effect sizes for differences in correlations between the P-scale scores of former BU patients and relatives, and with functional limitations and stigma.

<p>Spearman's rank correlations, 95% confidence intervals and effect sizes for differences in correlations between the P-scale scores of former BU patients and relatives, and with functional limitations and stigma.</p